3 quick facts on Integra LifeSciences’ financial outlook

Integra LifeSciences Holdings shares received a crowd sourced rating of four on a scale of one to five, on which five is a considered a “strong buy,” according to Uptick Analyst.

Advertisement

Here are three quick facts:

 

1. Zacks’ analysts estimate the company shares will hit between $55 and $80 in the next year.

 

2. Zacks’ analysts gave Integra LifeSciences an average broker rating of 1.85.

 

3. Integra LifeSciences Holdings’ headquarters are in Plainsboro, N.J.

 

More articles on devices:
EOS imaging partners with Spinologics — 5 highlights
Technavio: Global reverse shoulder arthroplasty market to grow — 5 takeaways
National Science Foundation awards SBIR grant to OsteoVantage — 4 notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.